Is oxygen a key factor in the lipodystrophy phenotype?

Lipids in Health and Disease

Volumn 5, Issue , 2006, Pages

  Gentil, Christel ^a,b   Le Jan, Sébastien ^c   Philippe, Josette ^c   Leibowitch, Jacques ^d   Sonigo, Pierre ^a   Germain, Stéphane ^c,e   Piétri Rouxel, France ^a,b  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c INSERM   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ADIPOGENESIS; ADIPOSE TISSUE CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; LIPODYSTROPHY; OXYGEN TENSION; PHENOTYPE; PROTEIN EXPRESSION;

ADIPOGENESIS; ADIPOSE TISSUE; ANOXIA; CELLS, CULTURED; DNA, MITOCHONDRIAL; GENE EXPRESSION REGULATION; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LEPTIN; OLIGOPEPTIDES; OXYGEN; PHENOTYPE; PPAR GAMMA; REVERSE TRANSCRIPTASE INHIBITORS; SOMATOSTATIN; TRIGLYCERIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33750435545     PISSN: 1476511X     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-5-27     Document Type: Article

References (39)

1. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA: Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. Aids 2001, 15(7):847-855.
2. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, et al.: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359(9311):1026-1031.
3. Lewis W: Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 2003, 58(3):189-197.
4. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B, Mallal S: Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. Aids 2003, 17(9):1329-1338.
5. Nolan D, Mallal S: The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J HIV Ther 2004, 9(2):34-40.
6. Petit C, Pietri-Rouxel F, Lesne A, Leste-Lasserre T, Mathez D, Naviaux RK, Sonigo P, Bouillaud F, Leibowitch J: Oxygen consumption by cultured human cells is impaired by a nucleoside analogue cocktail that inhibits mitochondrial DNA synthesis. Mitochondrion 2005, 5(3):154-161.
7. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M: Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006, 11(1):25-34.
8. Hammond E, Nolan D, James I, Metcalf C, Mallal S: Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. Aids 2004, 18(5):815-817.
9. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, et al.: In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005, 191(10):1686-1696.
10. Lafontan M, Berlan M: Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003, 24(6):276-283.
11. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145(5):2273-2282.
12. Yun Z, Maecker HL, Johnson RS, Giaccia AJ: Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2002, 2(3):331-341.
13. Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, Soukas A, Friedman JM, Holmes WE, Spiegelman BM: Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000, 20(14):5343-5349.
14. Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, Philippe J, Sibony M, Gasc JM, Corvol P, et al.: Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003, 162(5):1521-1528.
15. Ito Y, Oike Y, Yasunaga K, Hamada K, Miyata K, Matsumoto S, Sugano S, Tanihara H, Masuho Y, Suda T: Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res 2003, 63(20):6651-6657.
16. Dallabrida SM, Zurakowski D, Shih SC, Smith LE, Folkman J, Moulton KS, Rupnick MA: Adipose tissue growth and regression are regulated by angiopoietin-1. Biochem Biophys Res Commun 2003, 311(3):563-571.
17. Liu L, Meydani M: Angiogenesis inhibitors may regulate adiposity. Nutr Rev 2003, 61(11):384-387.
18. Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK: Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res 2003, 93(9):e88-97.
19. Fliers E, Sauerwein HP, Romijn JA, Reiss P, van der Valk M, Kalsbeek A, Kreier F, Buijs RM: HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet 2003, 362(9397):1758-1760.
20. Galli M, Gervasoni C, Ridolfo AL, Trabattoni D, Santambrogio S, Vaccarezza M, Meroni L, Trifiro G, Moroni M, Norbiato G, et al.: Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting. Aids 2003, 17(Suppl 1):S155-161.
21. Lolmede K, Durand de Saint Front V, Galitzky J, Lafontan M, Bouloumie A: Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes. Int J Obes Relat Metab Disord 2003, 27(10):1187-1195.
22. Fink T, Abildtrup L, Fogd K, Abdallah BM, Kassem M, Ebbesen P, Zachar V: Induction of adipocyte-like phenotype in human mesenchymal stem cells by hypoxia. Stem Cells 2004, 22(7):1346-1355.
23. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W: Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000, 275(37):28488-28493.
24. Yoshida K, Shimizugawa T, Ono M, Furukawa H: Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res 2002, 43(11):1770-1772.
25. Hattori K, Sumi T, Yasui T, Morimura M, Nobeyama H, Okamoto E, Noriyuki M, Honda K, Kiyama H, Ishiko O: VEGF mRNA in adipocytes increase with rebound weight-gain after diet-restriction. Int J Mol Med 2004, 13(3):395-399.
26. Hausman GJ, Richardson RL: Adipose tissue angiogenesis. J Anim Sci 2004, 82(3):925-934.
27. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ: Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002, 99(16):10730-10735.
28. Bouloumie A, Drexler HC, Lafontan M, Busse R: Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998, 83(10):1059-1066.
29. Artwohl M, Roden M, Holzenbein T, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM: Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord 2002, 26(4):577-580.
30. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, Spencer-Hansch C, Graf K, Nurnberg B, Law RE, et al.: Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 2002, 40(5):748-754.
31. Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M: Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002, 277(45):42953-42957.
32. Hagen T, Taylor CT, Lam F, Moncada S: Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003, 302(5652):1975-1978.
33. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7(1):77-85.
34. Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A: Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004, 110(3):349-355.
35. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK: Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 1997, 67(2):147-154.
36. Hazan U, Romero IA, Cancello R, Valente S, Perrin V, Mariot V, Dumonceaux J, Gerhardt CC, Strosberg AD, Couraud PO, et al.: Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors: a new target cell type for the immunodeficiency virus-1? Faseb J 2002, 16(10):1254-1256.
37. Zilberfarb V, Pietri-Rouxel F, Jockers R, Krief S, Delouis C, Issad T, Strosberg AD: Human immortalized brown adipocytes express functional beta3-adrenoceptor coupled to lipolysis. J Cell Sci 1997, 110(Pt 7):801-807.
38. Petit C, Mathez D, Barthelemy C, Leste-Lasserre T, Naviaux RK, Sonigo P, Leibowitch J: Quantitation of Blood Lymphocyte Mitochondrial DNA for the Monitoring of Antiretroviral Drug-Induced Mitochondrial DNA Depletion. J Acquir Immune Defic Syndr 2003, 33(4):461-469.
39. Paradis V, Bieche I, Dargere D, Bonvoust F, Ferlicot S, Olivi M, Lagha NB, Blanchet P, Benoit G, Vidaud M, et al.: hTERT expression in sporadic renal cell carcinomas. J Pathol 2001, 195(2):209-217.